<p>, /PRNewswire/ -- 罗森律师事务所是一家全球投资者权益法律事务所，宣布代表在 2025 年 9 月 24 日至 2025 年 10 月 31 日（包括该日期）期间购买 uniQure N.V.（NASDAQ: QURE）普通股的投资者提起集体诉讼（“集体诉讼期间”）。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 4 月 13 日之前向法院提出申请。</p>
<p>那么，您需要知道的是：如果您在集体诉讼期间购买了 uniQure 的普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该怎么做：要加入 uniQure 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=53025 或拨打免费电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 4 月 13 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。这些事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，被告错误陈述和/或未披露以下内容：（1）uniQure 的关键研究（针对亨廷顿病患者的 uniQure 领先药物候选者的研究）的设计——包括将关键研究结果与 ENROLL-HD 外部历史数据集进行比较——并未获得美国食品药品监督管理局（“FDA”）的完全批准；（2）被告淡化了尽管关键研究结果声称非常成功，uniQure 仍需推迟其生物制品许可申请（“BLA”）时间表以进行额外研究以补充其 BLA 提交的可能性；（3）因此，被告关于 uniQure 的业务、运营和前景的陈述缺乏合理基础。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 uniQure 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=53025 或拨打免费电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。在集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请在 LinkedIn 上关注我们以获取更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约， NY 10016</p>
<p>电话: (212) 686-1060</p>
<p>免费电话: (866) 767-3653</p>
<p>传真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI3Jk5ld3NJdGVtSWQ9REM5ODAzMCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjcxNjQ4UFJfTkVXU19VU1BSX19fX19EQzk4MDMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI3Jk5ld3NJdGVtSWQ9REM5ODAzMCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjcxNjQ4UFJfTkVXU19VU1BSX19fX19EQzk4MDMw"/></p>

QURE

<p>罗森律师事务所宣布对在 2025 年 9 月 24 日至 2025 年 10 月 31 日期间购买 uniQure N.V.（NASDAQ: QURE）股票的投资者提起集体诉讼。投资者可能有权获得无需预付费用的赔偿。诉讼声称 uniQure 对其关键研究的批准状态进行了虚假陈述，并淡化了其生物制品许可证申请可能出现延迟的可能性。感兴趣的投资者可以在 2026 年 4 月 13 日之前联系该事务所加入集体诉讼</p>

<p>, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 罗森律师事务所是一家全球投资者权益法律事务所，宣布代表在 2025 年 9 月 24 日至 2025 年 10 月 31 日（包括该日期）期间购买 uniQure N.V.（NASDAQ: QURE）普通股的投资者提起集体诉讼（“集体诉讼期间”）。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 4 月 13 日之前向法院提出申请。</p>
</div><p>So What: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么，您需要知道的是：如果您在集体诉讼期间购买了 uniQure 的普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该怎么做：要加入 uniQure 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=53025 或拨打免费电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 4 月 13 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。这些事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food and Drug Administration (the &#34;FDA&#34;); (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (&#34;BLA&#34;) timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants' statements about uniQure's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，被告错误陈述和/或未披露以下内容：（1）uniQure 的关键研究（针对亨廷顿病患者的 uniQure 领先药物候选者的研究）的设计——包括将关键研究结果与 ENROLL-HD 外部历史数据集进行比较——并未获得美国食品药品监督管理局（“FDA”）的完全批准；（2）被告淡化了尽管关键研究结果声称非常成功，uniQure 仍需推迟其生物制品许可申请（“BLA”）时间表以进行额外研究以补充其 BLA 提交的可能性；（3）因此，被告关于 uniQure 的业务、运营和前景的陈述缺乏合理基础。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 uniQure 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=53025 或拨打免费电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。在集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请在 LinkedIn 上关注我们以获取更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI3Jk5ld3NJdGVtSWQ9REM5ODAzMCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjcxNjQ4UFJfTkVXU19VU1BSX19fX19EQzk4MDMw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC98030&amp;Transmission_Id=202602271648PR_NEWS_USPR_____DC98030&amp;DateId=20260227"/></p>

QURE 的投资者有机会主导 Uniqure N.V.的证券欺诈诉讼